Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
- Autores
- Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; Mwinyella, Timothy; Spiga, Lisa; Piepenburg, Sven; Horstmann, Hauke; Olawale, Tijani; Li, Xiaowei; Mitre, Lucia Sol; Gissler, Mark Colin; Bugger, Heiko; Zirlik, Andreas; Heidt, Timo; Hilgendorf, Ingo; Stachon, Peter; von zur Muehlen, Constantin; Bode, Christoph; Wolf, Dennis
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future.
Fil: Marchini, Timoteo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania
Fil: Malchow, Sara. Albert Ludwigs University of Freiburg; Alemania
Fil: Caceres, Lourdes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania
Fil: El Rabih, Abed Al Hadi. Albert Ludwigs University of Freiburg; Alemania
Fil: Hansen, Sophie. Albert Ludwigs University of Freiburg; Alemania
Fil: Mwinyella, Timothy. Albert Ludwigs University of Freiburg; Alemania
Fil: Spiga, Lisa. Albert Ludwigs University of Freiburg; Alemania
Fil: Piepenburg, Sven. Albert Ludwigs University of Freiburg; Alemania
Fil: Horstmann, Hauke. Albert Ludwigs University of Freiburg; Alemania
Fil: Olawale, Tijani. Albert Ludwigs University of Freiburg; Alemania
Fil: Li, Xiaowei. Albert Ludwigs University of Freiburg; Alemania
Fil: Mitre, Lucia Sol. Albert Ludwigs University of Freiburg; Alemania
Fil: Gissler, Mark Colin. Albert Ludwigs University of Freiburg; Alemania
Fil: Bugger, Heiko. University of Graz; Austria
Fil: Zirlik, Andreas. University of Graz; Austria
Fil: Heidt, Timo. Albert Ludwigs University of Freiburg; Alemania
Fil: Hilgendorf, Ingo. Albert Ludwigs University of Freiburg; Alemania
Fil: Stachon, Peter. Albert Ludwigs University of Freiburg; Alemania
Fil: von zur Muehlen, Constantin. Albert Ludwigs University of Freiburg; Alemania
Fil: Bode, Christoph. Albert Ludwigs University of Freiburg; Alemania
Fil: Wolf, Dennis. Albert Ludwigs University of Freiburg; Alemania - Materia
-
APOB
ATHEROSCLEROSIS
AUTO-ANTIBODIES
CARDIOVASCULAR DISEASE
IMMUNITY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/204732
Ver los metadatos del registro completo
id |
CONICETDig_90484e853cdd0ff39b12ea7398c7bba4 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/204732 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic DiseaseMarchini, Timoteo OscarMalchow, SaraCaceres, LourdesEl Rabih, Abed Al HadiHansen, SophieMwinyella, TimothySpiga, LisaPiepenburg, SvenHorstmann, HaukeOlawale, TijaniLi, XiaoweiMitre, Lucia SolGissler, Mark ColinBugger, HeikoZirlik, AndreasHeidt, TimoHilgendorf, IngoStachon, Petervon zur Muehlen, ConstantinBode, ChristophWolf, DennisAPOBATHEROSCLEROSISAUTO-ANTIBODIESCARDIOVASCULAR DISEASEIMMUNITYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future.Fil: Marchini, Timoteo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; AlemaniaFil: Malchow, Sara. Albert Ludwigs University of Freiburg; AlemaniaFil: Caceres, Lourdes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; AlemaniaFil: El Rabih, Abed Al Hadi. Albert Ludwigs University of Freiburg; AlemaniaFil: Hansen, Sophie. Albert Ludwigs University of Freiburg; AlemaniaFil: Mwinyella, Timothy. Albert Ludwigs University of Freiburg; AlemaniaFil: Spiga, Lisa. Albert Ludwigs University of Freiburg; AlemaniaFil: Piepenburg, Sven. Albert Ludwigs University of Freiburg; AlemaniaFil: Horstmann, Hauke. Albert Ludwigs University of Freiburg; AlemaniaFil: Olawale, Tijani. Albert Ludwigs University of Freiburg; AlemaniaFil: Li, Xiaowei. Albert Ludwigs University of Freiburg; AlemaniaFil: Mitre, Lucia Sol. Albert Ludwigs University of Freiburg; AlemaniaFil: Gissler, Mark Colin. Albert Ludwigs University of Freiburg; AlemaniaFil: Bugger, Heiko. University of Graz; AustriaFil: Zirlik, Andreas. University of Graz; AustriaFil: Heidt, Timo. Albert Ludwigs University of Freiburg; AlemaniaFil: Hilgendorf, Ingo. Albert Ludwigs University of Freiburg; AlemaniaFil: Stachon, Peter. Albert Ludwigs University of Freiburg; AlemaniaFil: von zur Muehlen, Constantin. Albert Ludwigs University of Freiburg; AlemaniaFil: Bode, Christoph. Albert Ludwigs University of Freiburg; AlemaniaFil: Wolf, Dennis. Albert Ludwigs University of Freiburg; AlemaniaFrontiers Media2022-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/204732Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; et al.; Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease; Frontiers Media; Frontiers in Cardiovascular Medicine; 9; 4-2022; 1-112297-055XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fcvm.2022.826729/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fcvm.2022.826729info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:45:01Zoai:ri.conicet.gov.ar:11336/204732instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:45:01.622CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease |
title |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease |
spellingShingle |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease Marchini, Timoteo Oscar APOB ATHEROSCLEROSIS AUTO-ANTIBODIES CARDIOVASCULAR DISEASE IMMUNITY |
title_short |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease |
title_full |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease |
title_fullStr |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease |
title_full_unstemmed |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease |
title_sort |
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease |
dc.creator.none.fl_str_mv |
Marchini, Timoteo Oscar Malchow, Sara Caceres, Lourdes El Rabih, Abed Al Hadi Hansen, Sophie Mwinyella, Timothy Spiga, Lisa Piepenburg, Sven Horstmann, Hauke Olawale, Tijani Li, Xiaowei Mitre, Lucia Sol Gissler, Mark Colin Bugger, Heiko Zirlik, Andreas Heidt, Timo Hilgendorf, Ingo Stachon, Peter von zur Muehlen, Constantin Bode, Christoph Wolf, Dennis |
author |
Marchini, Timoteo Oscar |
author_facet |
Marchini, Timoteo Oscar Malchow, Sara Caceres, Lourdes El Rabih, Abed Al Hadi Hansen, Sophie Mwinyella, Timothy Spiga, Lisa Piepenburg, Sven Horstmann, Hauke Olawale, Tijani Li, Xiaowei Mitre, Lucia Sol Gissler, Mark Colin Bugger, Heiko Zirlik, Andreas Heidt, Timo Hilgendorf, Ingo Stachon, Peter von zur Muehlen, Constantin Bode, Christoph Wolf, Dennis |
author_role |
author |
author2 |
Malchow, Sara Caceres, Lourdes El Rabih, Abed Al Hadi Hansen, Sophie Mwinyella, Timothy Spiga, Lisa Piepenburg, Sven Horstmann, Hauke Olawale, Tijani Li, Xiaowei Mitre, Lucia Sol Gissler, Mark Colin Bugger, Heiko Zirlik, Andreas Heidt, Timo Hilgendorf, Ingo Stachon, Peter von zur Muehlen, Constantin Bode, Christoph Wolf, Dennis |
author2_role |
author author author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
APOB ATHEROSCLEROSIS AUTO-ANTIBODIES CARDIOVASCULAR DISEASE IMMUNITY |
topic |
APOB ATHEROSCLEROSIS AUTO-ANTIBODIES CARDIOVASCULAR DISEASE IMMUNITY |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future. Fil: Marchini, Timoteo Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania Fil: Malchow, Sara. Albert Ludwigs University of Freiburg; Alemania Fil: Caceres, Lourdes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina. Albert Ludwigs University of Freiburg; Alemania Fil: El Rabih, Abed Al Hadi. Albert Ludwigs University of Freiburg; Alemania Fil: Hansen, Sophie. Albert Ludwigs University of Freiburg; Alemania Fil: Mwinyella, Timothy. Albert Ludwigs University of Freiburg; Alemania Fil: Spiga, Lisa. Albert Ludwigs University of Freiburg; Alemania Fil: Piepenburg, Sven. Albert Ludwigs University of Freiburg; Alemania Fil: Horstmann, Hauke. Albert Ludwigs University of Freiburg; Alemania Fil: Olawale, Tijani. Albert Ludwigs University of Freiburg; Alemania Fil: Li, Xiaowei. Albert Ludwigs University of Freiburg; Alemania Fil: Mitre, Lucia Sol. Albert Ludwigs University of Freiburg; Alemania Fil: Gissler, Mark Colin. Albert Ludwigs University of Freiburg; Alemania Fil: Bugger, Heiko. University of Graz; Austria Fil: Zirlik, Andreas. University of Graz; Austria Fil: Heidt, Timo. Albert Ludwigs University of Freiburg; Alemania Fil: Hilgendorf, Ingo. Albert Ludwigs University of Freiburg; Alemania Fil: Stachon, Peter. Albert Ludwigs University of Freiburg; Alemania Fil: von zur Muehlen, Constantin. Albert Ludwigs University of Freiburg; Alemania Fil: Bode, Christoph. Albert Ludwigs University of Freiburg; Alemania Fil: Wolf, Dennis. Albert Ludwigs University of Freiburg; Alemania |
description |
Rationale: Atherosclerosis is a chronic inflammatory disease of large arteries that involves an autoimmune response with autoreactive T cells and auto-antibodies recognizing Apolipoprotein B (ApoB), the core protein of low-density lipoprotein (LDL). Here, we aimed to establish a clinical association between circulating human ApoB auto-antibodies with atherosclerosis and its clinical risk factors using a novel assay to detect auto-antibodies against a pool of highly immunogenic ApoB-peptides. Methods and Results: To detect polyclonal IgM- and IgG-antibodies recognizing ApoB, we developed a chemiluminescent sandwich ELISA with 30 ApoB peptides selected by an in silico assay for a high binding affinity to MHC-II, which cover more than 80% of known MHC-II variants in a Caucasian population. This pre-selection of immunogenic self-peptides accounted for the high variability of human MHC-II, which is fundamental to allow T cell dependent generation of IgG antibodies. We quantified levels of ApoB-autoantibodies in a clinical cohort of 307 patients that underwent coronary angiography. Plasma anti-ApoB IgG and IgM concentrations showed no differences across healthy individuals (n = 67), patients with coronary artery disease (n = 179), and patients with an acute coronary syndrome (n = 61). However, plasma levels of anti-ApoB IgG, which are considered pro-inflammatory, were significantly increased in patients with obesity (p = 0.044) and arterial hypertension (p < 0.0001). In addition, patients diagnosed with the metabolic syndrome showed significantly elevated Anti-ApoB IgG (p = 0.002). Even when normalized for total plasma IgG, anti-ApoB IgG remained highly upregulated in hypertensive patients (p < 0.0001). We observed no association with triglycerides, total cholesterol, VLDL, or LDL plasma levels. However, total and normalized anti-ApoB IgG levels negatively correlated with HDL. In contrast, total and normalized anti-ApoB IgM, that have been suggested as anti-inflammatory, were significantly lower in diabetic patients (p = 0.012) and in patients with the metabolic syndrome (p = 0.005). Conclusion: Using a novel ELISA method to detect auto-antibodies against ApoB in humans, we show that anti-ApoB IgG associate with cardiovascular risk factors but not with the clinical appearance of atherosclerosis, suggesting that humoral immune responses against ApoB are shaped by cardiovascular risk factors but not disease status itself. This novel tool will be helpful to develop immune-based risk stratification for clinical atherosclerosis in the future. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/204732 Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; et al.; Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease; Frontiers Media; Frontiers in Cardiovascular Medicine; 9; 4-2022; 1-11 2297-055X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/204732 |
identifier_str_mv |
Marchini, Timoteo Oscar; Malchow, Sara; Caceres, Lourdes; El Rabih, Abed Al Hadi; Hansen, Sophie; et al.; Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease; Frontiers Media; Frontiers in Cardiovascular Medicine; 9; 4-2022; 1-11 2297-055X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fcvm.2022.826729/full info:eu-repo/semantics/altIdentifier/doi/10.3389/fcvm.2022.826729 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842268704326287360 |
score |
13.13397 |